NPM1 and acute myeloid leukemia: In conclusion, even if further experiments on the potential synergy of aggregation of the entire AML-mutated protein are required, the presented data allow adding new gussets in the puzzled way of molecular determinants of cytoplasmatic accumulation of NPMc+ and could introduce innovative therapeutic strategies targeting the NPM1-AML subtype.